National Surgical Adjuvant Study of Breast Cancer(N-SAS BC) 07 [RESPECT]
Status:
Completed
Trial end date:
2018-10-15
Target enrollment:
Participant gender:
Summary
To investigate clinical positioning between trastuzumab (Herceptin) monotherapy (H group) and
combination therapy of trastuzumab and chemotherapy (H+CT group) based on a randomized
controlled trial in women over 70 years with human epidermal growth factor receptor type-2
(HER2) positive primary breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Comprehensive Support Project for Oncology Research